Depression of polyamine synthesis in L1210 leukemic mice during treatment with a potent antileukemic agent, 5-azacytidine.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use; D002262:Carboxy-Lyases / Q000032:analysis; D003562:Cytidine / Q000627:therapeutic use*; D003864:Depression, Chemical; D004794:Enzyme Repression; D007274:Injections, Intraperitoneal; D007939:Leukemia L1210 / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism*; D008099:Liver / Q000032:analysis / Q000378:metabolism; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D009929:Organ Size; D009952:Ornithine; D011073:Polyamines / Q000032:analysis / Q000096:biosynthesis*; D011700:Putrescine / Q000032:analysis; D012436:S-Adenosylmethionine; D013095:Spermidine / Q000032:analysis; D013154:Spleen / Q000032:analysis / Q000201:enzymology / Q000378:metabolism; D014227:Triazines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011073:Polyamines; D014227:Triazines; D003562:Cytidine; D012436:S-Adenosylmethionine; D009952:Ornithine; D002262:Carboxy-Lyases; D001374:Azacitidine; D013095:Spermidine; D011700:Putrescine